Overview

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QAU145 in Patients With Cystic Fibrosis

Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This study will investigate the safety, tolerability, pharmacokinetic, and pharmacodynamic response of patients with cystic fibrosis to administration of QAU145 via intranasal spray.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals